WO1994017819A1 - Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant - Google Patents
Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant Download PDFInfo
- Publication number
- WO1994017819A1 WO1994017819A1 PCT/US1994/001239 US9401239W WO9417819A1 WO 1994017819 A1 WO1994017819 A1 WO 1994017819A1 US 9401239 W US9401239 W US 9401239W WO 9417819 A1 WO9417819 A1 WO 9417819A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- surfactant
- poloxamer
- rbpi
- polysorbate
- bpi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94907963A EP0682524B1 (en) | 1993-02-02 | 1994-02-02 | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
DE69428521T DE69428521T2 (en) | 1993-02-02 | 1994-02-02 | MEDICINAL COMPOSITIONS CONTAINING A BACTERICIDAL PERMEABILITY-INCREASING PROTEIN AND A SURFACTANT |
DK94907963T DK0682524T3 (en) | 1993-02-02 | 1994-02-02 | Pharmaceutical compositions containing a bactericide / permeability enhancing protein and a relaxant |
JP51821394A JP3946246B2 (en) | 1993-02-02 | 1994-02-02 | Pharmaceutical composition containing bactericidal / permeability improving protein (BPI) and surfactant |
AT94907963T ATE206308T1 (en) | 1993-02-02 | 1994-02-02 | MEDICINAL COMPOSITIONS CONTAINING A BACTERICIDAL PERMEABILITY-INCREASE PROTEIN AND A SURFACTANT |
AU61330/94A AU695125B2 (en) | 1993-02-02 | 1994-02-02 | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
HK98115456A HK1014156A1 (en) | 1993-02-02 | 1998-12-24 | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1236093A | 1993-02-02 | 1993-02-02 | |
US08/012,360 | 1993-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994017819A1 true WO1994017819A1 (en) | 1994-08-18 |
Family
ID=21754603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/001239 WO1994017819A1 (en) | 1993-02-02 | 1994-02-02 | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
Country Status (13)
Country | Link |
---|---|
US (5) | US5488034A (en) |
EP (1) | EP0682524B1 (en) |
JP (2) | JP3946246B2 (en) |
CN (1) | CN1163264C (en) |
AT (1) | ATE206308T1 (en) |
AU (1) | AU695125B2 (en) |
CA (1) | CA2155005C (en) |
DE (1) | DE69428521T2 (en) |
DK (1) | DK0682524T3 (en) |
ES (1) | ES2164098T3 (en) |
HK (1) | HK1014156A1 (en) |
PT (1) | PT682524E (en) |
WO (1) | WO1994017819A1 (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
US5523288A (en) * | 1993-09-22 | 1996-06-04 | Xoma Corporation | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic |
WO1996021436A1 (en) * | 1995-01-13 | 1996-07-18 | Xoma Corporation | Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products |
US5578572A (en) * | 1994-01-14 | 1996-11-26 | Xoma Corporation | Anti-gram-positive bacterial methods and materials |
US5627153A (en) * | 1994-01-14 | 1997-05-06 | Xoma Corporation | Anti-fungal methods and materials |
WO1997017989A1 (en) * | 1995-11-14 | 1997-05-22 | Xoma Corporation | Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation |
WO1997017990A1 (en) * | 1995-11-14 | 1997-05-22 | Xoma Corporation | Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
US5696090A (en) * | 1993-02-02 | 1997-12-09 | Xoma Corporation | Pharmaceutical composition |
US5731415A (en) * | 1993-06-17 | 1998-03-24 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
US5756464A (en) * | 1996-05-23 | 1998-05-26 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5821064A (en) * | 1993-09-22 | 1998-10-13 | Xoma Corporation | Method of screening for an active inflammatory state by determining the concentration of extracellular BPI |
US5830860A (en) * | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5856302A (en) * | 1994-03-11 | 1999-01-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5856438A (en) * | 1993-03-12 | 1999-01-05 | Xoma Corporation | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US5858974A (en) * | 1995-07-20 | 1999-01-12 | Xoma Corporation | Anti-fungal peptides |
US5888977A (en) * | 1996-05-10 | 1999-03-30 | Giroir; Brett P. | Therapeutic uses of BPI protein products for human meningococcemia |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US5932544A (en) * | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US5990082A (en) * | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US6051553A (en) * | 1993-07-14 | 2000-04-18 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US6482796B2 (en) | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US6486125B1 (en) | 1996-05-24 | 2002-11-26 | Regents Of The University Of Minnesota | Synthesis of soluble β-sheet forming peptides |
EP1304118A2 (en) * | 1996-11-01 | 2003-04-23 | XOMA Technology Ltd. | Therapeutic uses and formulations for BPI protein products. |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
EP1539212A2 (en) * | 2002-07-12 | 2005-06-15 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
US20050287156A1 (en) * | 2002-11-26 | 2005-12-29 | Eurocine Ab | Novel amine-based adjuvant |
US7339023B2 (en) | 2002-02-20 | 2008-03-04 | Regents Of The University Of Minnesota | Partial peptide mimetics and methods |
WO2013041850A3 (en) * | 2011-09-21 | 2013-09-26 | University College Cardiff Consultants Limited | Inhalable microemulsion comprising anaesthetic |
US20130295077A1 (en) * | 2010-06-25 | 2013-11-07 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277410B1 (en) | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
US6153193A (en) * | 1993-04-28 | 2000-11-28 | Supratek Pharma Inc. | Compositions for targeting biological agents |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
AU6358898A (en) | 1996-09-09 | 1998-04-17 | Alexander V Kabanov | Fluorinated copolymeric pharmaceutical adjuncts |
US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
FR2764800B1 (en) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN DERIVATIVES |
US20030166525A1 (en) | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
ATE375167T1 (en) * | 1999-04-21 | 2007-10-15 | Us Gov Health & Human Serv | UTEROGLOBIN FOR THE TREATMENT OF IGA-MEDIATED AUTOIMMUNE DISEASES |
US6413537B1 (en) | 2000-03-10 | 2002-07-02 | Wisconsin Alumni Research Foundation | Nystatin formulation having reduced toxicity |
US7256180B2 (en) | 2000-04-28 | 2007-08-14 | Supratek Pharma Inc. | Compositions and methods for inducing activation of dendritic cells |
BR0213298A (en) * | 2001-10-16 | 2006-11-07 | Rxkinetix Inc | high protein formulations and manufacturing process |
WO2004075913A1 (en) * | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparation containing protein |
WO2004087213A1 (en) | 2003-04-02 | 2004-10-14 | Ares Trading S.A. | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
US7838721B2 (en) * | 2003-04-09 | 2010-11-23 | Paragon Trade Brands, Llc | Disposable articles using high column AUL superabsorbents |
PT1638595E (en) * | 2003-06-20 | 2013-04-26 | Ares Trading Sa | Freeze-dried fsh / lh formulations |
US8377459B2 (en) * | 2003-07-09 | 2013-02-19 | The Procter & Gamble Company | Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin |
US20050220881A1 (en) * | 2003-10-10 | 2005-10-06 | Bvm Holding Co. | Pharmaceutical composition |
US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
WO2006013370A1 (en) * | 2004-08-04 | 2006-02-09 | Ipsen Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
EP2813239B1 (en) * | 2004-08-04 | 2017-03-22 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin A2 |
US20060173428A1 (en) * | 2005-02-02 | 2006-08-03 | Acors Deanna M | Absorbent article with logically correlated image and textual graphics |
US7964200B2 (en) | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
CU23432B6 (en) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS |
WO2009021173A1 (en) * | 2007-08-08 | 2009-02-12 | Advanced Liquid Logic, Inc. | Use of additives for enhancing droplet operations |
JP5387850B2 (en) * | 2007-09-12 | 2014-01-15 | Jsr株式会社 | Protein stabilizer and method for producing the same, method for using protein stabilizer, and method for stabilizing protein |
KR101784231B1 (en) | 2008-06-20 | 2017-11-08 | 노파르티스 아게 | Immunoglobulins with reduced aggregation |
PL2437785T3 (en) | 2009-06-04 | 2015-08-31 | Novartis Ag | METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION |
CN105541978B (en) | 2010-09-15 | 2019-12-13 | 兰德尔·J·米斯尼 | Systems and methods for delivering bioactive agents using bacterial toxin-derived transport sequences |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
KR102598038B1 (en) | 2014-05-07 | 2023-11-07 | 어플라이드 몰레큘라 트랜스포트 인크. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
CA3093386A1 (en) | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
PL3762009T3 (en) | 2018-03-08 | 2022-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
WO2021034727A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
WO2021187897A1 (en) * | 2020-03-18 | 2021-09-23 | (주)지아이이노베이션 | Fusion protein preparation comprising il-2 and cd80 proteins |
AU2022245592A1 (en) * | 2021-03-24 | 2023-10-19 | Jcr Pharmaceuticals Co., Ltd. | Stable aqueous pharmaceutical composition or freeze-dried pharmaceutical composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001486A1 (en) * | 1987-08-11 | 1989-02-23 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4478829A (en) * | 1983-04-28 | 1984-10-23 | Armour Pharmaceutical Company | Pharmaceutical preparation containing purified fibronectin |
US4933179A (en) * | 1983-08-22 | 1990-06-12 | Syntex (U.S.A.) Inc. | Feline leukemia virus antigen vaccines |
DE3406497A1 (en) * | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION |
US5234683A (en) * | 1985-06-18 | 1993-08-10 | Emory University | Method of stimulating the immune system |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5152979A (en) * | 1986-05-15 | 1992-10-06 | Emory University | Method for treating vascular obstructions caused by abnormal cells |
US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
FR2608988B1 (en) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES |
FR2634397B2 (en) * | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES |
JPH01503458A (en) * | 1987-02-20 | 1989-11-22 | エモリ ユニバーシティ | anti-infective compounds |
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
FR2630115B1 (en) * | 1988-04-14 | 1994-10-28 | Merieux Inst | PROCESS FOR STABILIZING HUMAN ALBUMIN SOLUTIONS AND SOLUTION OBTAINED |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
JPH02107163A (en) * | 1988-10-15 | 1990-04-19 | Suntory Ltd | Production of novel gelatinous food |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5334584A (en) * | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US4997664A (en) * | 1989-09-05 | 1991-03-05 | Bryan Foods, Inc. | Method for packaging food products |
EP0563222B1 (en) * | 1990-12-03 | 1998-02-25 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
CA2106474C (en) * | 1991-03-19 | 2004-02-10 | R. Martin Emanuele | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5234908A (en) * | 1991-04-12 | 1993-08-10 | Creative Biomolecules, Inc. | Method of treating gastrointestinal ulcers with platelet derived growth factor |
JPH07502642A (en) * | 1991-09-26 | 1995-03-23 | インサイト ファーマシューティカルズ,インコーポレイテッド | A novel form of liposaccharide binding protein (LBP) |
AU4382193A (en) * | 1992-05-19 | 1993-12-13 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
US5439807A (en) * | 1992-05-19 | 1995-08-08 | Xoma Corporation | Methods for the preparation of endotoxin-binding proteins |
DE69428521T2 (en) * | 1993-02-02 | 2002-05-23 | Xoma Technology Ltd | MEDICINAL COMPOSITIONS CONTAINING A BACTERICIDAL PERMEABILITY-INCREASING PROTEIN AND A SURFACTANT |
US5348942A (en) * | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
-
1994
- 1994-02-02 DE DE69428521T patent/DE69428521T2/en not_active Expired - Fee Related
- 1994-02-02 AU AU61330/94A patent/AU695125B2/en not_active Ceased
- 1994-02-02 ES ES94907963T patent/ES2164098T3/en not_active Expired - Lifetime
- 1994-02-02 PT PT94907963T patent/PT682524E/en unknown
- 1994-02-02 DK DK94907963T patent/DK0682524T3/en active
- 1994-02-02 AT AT94907963T patent/ATE206308T1/en not_active IP Right Cessation
- 1994-02-02 WO PCT/US1994/001239 patent/WO1994017819A1/en active IP Right Grant
- 1994-02-02 JP JP51821394A patent/JP3946246B2/en not_active Expired - Fee Related
- 1994-02-02 US US08/190,869 patent/US5488034A/en not_active Expired - Lifetime
- 1994-02-02 CA CA002155005A patent/CA2155005C/en not_active Expired - Fee Related
- 1994-02-02 EP EP94907963A patent/EP0682524B1/en not_active Expired - Lifetime
- 1994-02-02 CN CNB941913554A patent/CN1163264C/en not_active Expired - Fee Related
-
1995
- 1995-06-07 US US08/472,995 patent/US5696090A/en not_active Expired - Fee Related
-
1997
- 1997-12-08 US US08/986,413 patent/US5955427A/en not_active Expired - Fee Related
-
1998
- 1998-12-24 HK HK98115456A patent/HK1014156A1/en not_active IP Right Cessation
-
1999
- 1999-05-17 US US09/313,525 patent/US6066620A/en not_active Expired - Lifetime
-
2000
- 2000-02-11 US US09/502,356 patent/US6255284B1/en not_active Expired - Fee Related
-
2005
- 2005-02-25 JP JP2005052149A patent/JP2005145986A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001486A1 (en) * | 1987-08-11 | 1989-02-23 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827816A (en) * | 1993-02-02 | 1998-10-27 | Xoma Corporation | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US5955427A (en) * | 1993-02-02 | 1999-09-21 | Xoma Corporation | Pharmaceutical composition |
US6066620A (en) * | 1993-02-02 | 2000-05-23 | Xoma Corporation | Pharmaceutical compositions of bactericidal/permeability increasing protein (BPI) |
US6255284B1 (en) | 1993-02-02 | 2001-07-03 | Xoma Corporation | Pharmaceutical composition |
EP1310558A2 (en) * | 1993-02-02 | 2003-05-14 | XOMA Technology Ltd. | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
EP1310558A3 (en) * | 1993-02-02 | 2003-08-13 | XOMA Technology Ltd. | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US6828418B2 (en) | 1993-02-02 | 2004-12-07 | Xoma Corporation | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US6433140B1 (en) | 1993-02-02 | 2002-08-13 | Xoma Corporation | Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same |
US5674834A (en) * | 1993-02-02 | 1997-10-07 | Xoma Corporation | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
US5696090A (en) * | 1993-02-02 | 1997-12-09 | Xoma Corporation | Pharmaceutical composition |
US5856438A (en) * | 1993-03-12 | 1999-01-05 | Xoma Corporation | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
US6620785B2 (en) | 1993-03-12 | 2003-09-16 | Xoma Corporation | Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
US6376462B1 (en) | 1993-06-17 | 2002-04-23 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
US5731415A (en) * | 1993-06-17 | 1998-03-24 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
US6051553A (en) * | 1993-07-14 | 2000-04-18 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
US5821064A (en) * | 1993-09-22 | 1998-10-13 | Xoma Corporation | Method of screening for an active inflammatory state by determining the concentration of extracellular BPI |
US5523288A (en) * | 1993-09-22 | 1996-06-04 | Xoma Corporation | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic |
US6140306A (en) * | 1993-09-22 | 2000-10-31 | Xoma Corporation | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
US5578572A (en) * | 1994-01-14 | 1996-11-26 | Xoma Corporation | Anti-gram-positive bacterial methods and materials |
US5783561A (en) * | 1994-01-14 | 1998-07-21 | Xoma Corporation | Anti-gram-positive bacterial methods and materials |
US6054431A (en) * | 1994-01-14 | 2000-04-25 | Xoma Corporation | Anti-gram-positive bacterial methods and materials |
US5627153A (en) * | 1994-01-14 | 1997-05-06 | Xoma Corporation | Anti-fungal methods and materials |
US5990086A (en) * | 1994-01-24 | 1999-11-23 | Xoma Corporation | Therapeutic uses of BPI protein products for human meningococcemia |
US5856302A (en) * | 1994-03-11 | 1999-01-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US6277821B1 (en) | 1994-03-11 | 2001-08-21 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5830860A (en) * | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US6057293A (en) * | 1994-05-31 | 2000-05-02 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US6268345B1 (en) | 1994-05-31 | 2001-07-31 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US5932544A (en) * | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US6440936B2 (en) | 1994-07-11 | 2002-08-27 | Xoma Corporation | Anti-protozoan methods and materials |
US6013629A (en) * | 1994-07-11 | 2000-01-11 | Xoma Corporation | Anti-protozoan methods and materials |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
AU717640B2 (en) * | 1995-01-13 | 2000-03-30 | Xoma Corporation | Improved therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
EP1283050A2 (en) * | 1995-01-13 | 2003-02-12 | XOMA Technology Ltd. | Improved therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
EP1283050A3 (en) * | 1995-01-13 | 2004-01-21 | XOMA Technology Ltd. | Improved therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
WO1996021436A1 (en) * | 1995-01-13 | 1996-07-18 | Xoma Corporation | Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
US5858974A (en) * | 1995-07-20 | 1999-01-12 | Xoma Corporation | Anti-fungal peptides |
WO1997017990A1 (en) * | 1995-11-14 | 1997-05-22 | Xoma Corporation | Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury |
WO1997017989A1 (en) * | 1995-11-14 | 1997-05-22 | Xoma Corporation | Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation |
US6107280A (en) * | 1996-05-10 | 2000-08-22 | Xoma Corporation | Antithrombotic materials and methods |
US6242418B1 (en) | 1996-05-10 | 2001-06-05 | Xoma Corporation | Therapeutic uses of BPI protein products for human meningococcemia |
US5935930A (en) * | 1996-05-10 | 1999-08-10 | Xoma Corporation | Antithrombotic materials and methods |
US6599881B1 (en) | 1996-05-10 | 2003-07-29 | Xoma Corporation | Antithrombotic materials and methods |
US5888977A (en) * | 1996-05-10 | 1999-03-30 | Giroir; Brett P. | Therapeutic uses of BPI protein products for human meningococcemia |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
US6596691B2 (en) | 1996-05-10 | 2003-07-22 | Xoma Corporation | Therapeutic uses of BPI protein products for human meningococcemia |
US5945399A (en) * | 1996-05-23 | 1999-08-31 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
US5756464A (en) * | 1996-05-23 | 1998-05-26 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma |
US6486125B1 (en) | 1996-05-24 | 2002-11-26 | Regents Of The University Of Minnesota | Synthesis of soluble β-sheet forming peptides |
US7030087B2 (en) | 1996-05-24 | 2006-04-18 | Regents Of The University Of Minnesota | Synthetic approach to designed chemical structures |
US6583116B1 (en) | 1996-08-09 | 2003-06-24 | Xoma Corporation | Anti-chlamydial methods and materials |
US6162788A (en) * | 1996-08-09 | 2000-12-19 | Xoma Corporation | Uses of BPI protein products |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6482796B2 (en) | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
EP1304118A3 (en) * | 1996-11-01 | 2004-01-14 | XOMA Technology Ltd. | Therapeutic uses and formulations for BPI protein products. |
EP1304118A2 (en) * | 1996-11-01 | 2003-04-23 | XOMA Technology Ltd. | Therapeutic uses and formulations for BPI protein products. |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
US5990082A (en) * | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
US6306824B1 (en) | 1997-10-22 | 2001-10-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US6087126A (en) * | 1998-06-19 | 2000-07-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US6599880B1 (en) | 1998-06-19 | 2003-07-29 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US7339023B2 (en) | 2002-02-20 | 2008-03-04 | Regents Of The University Of Minnesota | Partial peptide mimetics and methods |
AU2003251906B2 (en) * | 2002-07-12 | 2008-12-04 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
EP1539212A2 (en) * | 2002-07-12 | 2005-06-15 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
EP1539212A4 (en) * | 2002-07-12 | 2007-05-02 | Medarex Inc | Methods and compositions for preventing oxidative degradation of proteins |
US20050287156A1 (en) * | 2002-11-26 | 2005-12-29 | Eurocine Ab | Novel amine-based adjuvant |
US20130295077A1 (en) * | 2010-06-25 | 2013-11-07 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
US9814764B2 (en) * | 2010-06-25 | 2017-11-14 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b by intrathecal administration of alpha-n-acetylglucosaminidase |
US11065307B2 (en) | 2010-06-25 | 2021-07-20 | Shire Human Genetic Therapies, Inc. | Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety |
US11260112B2 (en) | 2010-06-25 | 2022-03-01 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of iduronate-2-sulfatase |
WO2013041850A3 (en) * | 2011-09-21 | 2013-09-26 | University College Cardiff Consultants Limited | Inhalable microemulsion comprising anaesthetic |
US9827394B2 (en) | 2011-09-21 | 2017-11-28 | University College Cardiff Consultants Limited | Dispersion anaesthetic device |
EP3326677B1 (en) * | 2011-09-21 | 2022-06-22 | University College Cardiff Consultants Limited | Inhalable microemulsion comprising anaesthetic |
Also Published As
Publication number | Publication date |
---|---|
US5696090A (en) | 1997-12-09 |
US5955427A (en) | 1999-09-21 |
AU695125B2 (en) | 1998-08-06 |
CN1127992A (en) | 1996-07-31 |
DE69428521D1 (en) | 2001-11-08 |
EP0682524B1 (en) | 2001-10-04 |
AU6133094A (en) | 1994-08-29 |
CA2155005A1 (en) | 1994-08-18 |
JP2005145986A (en) | 2005-06-09 |
EP0682524A1 (en) | 1995-11-22 |
US6066620A (en) | 2000-05-23 |
JP3946246B2 (en) | 2007-07-18 |
CN1163264C (en) | 2004-08-25 |
DE69428521T2 (en) | 2002-05-23 |
JPH10513433A (en) | 1998-12-22 |
ATE206308T1 (en) | 2001-10-15 |
DK0682524T3 (en) | 2002-01-28 |
CA2155005C (en) | 1999-04-06 |
US5488034A (en) | 1996-01-30 |
HK1014156A1 (en) | 1999-09-24 |
ES2164098T3 (en) | 2002-02-16 |
US6255284B1 (en) | 2001-07-03 |
PT682524E (en) | 2002-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0682524B1 (en) | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant | |
AU2013211645B2 (en) | Stabilised protein compositions based on semifluorinated alkanes | |
ES2861898T3 (en) | Formulations comprising VEGF antagonists for intravitreal administration | |
JP5376573B2 (en) | VEGF antagonist preparation | |
ES2153385T5 (en) | MATERIAL COMPOSITION BASED ON HUMAN GROWTH HORMONE. | |
Kumar et al. | Modulation of the thermodynamic stability of proteins by polyols: significance of polyol hydrophobicity and impact on the chemical potential of water | |
JP2002511103A (en) | Amylin agonist peptide preparation | |
US6268345B1 (en) | Bactericidal/permeability-increasing protein (BPI) compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94191355.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994907963 Country of ref document: EP Ref document number: 2155005 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1994 518213 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1994907963 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994907963 Country of ref document: EP |